scholarly journals Monoclonal Antibody-Mediated Modulation of the Humoral Immune Response against Mucosally AppliedStreptococcus mutans

2000 ◽  
Vol 68 (4) ◽  
pp. 1796-1805 ◽  
Author(s):  
L. Jeannine Brady ◽  
Marloes L. J. A. van Tilburg ◽  
Connie E. Alford ◽  
William P. McArthur

ABSTRACT Systemic immunization with antigen coupled to monoclonal antibody (MAb) has been used by several investigators to increase the number of MAb-producing hybridomas against an antigen and to elicit antibodies specific for poorly immunogenic epitopes. This strategy has implications for vaccine design in that protective immunity is not necessarily directed at immunodominant epitopes of pathogens and may be improved by deliberately shifting the immune response toward subdominant epitopes. To our knowledge, no studies to date have addressed the potential for immunomodulatory activity mediated by MAbs bound to mucosally applied antigen. To test whether administration of an exogenous MAb directed against a streptococcal surface protein could influence the humoral immune response, BALB/c mice were immunized orally by gastric intubation or intranasally with Streptococcus mutans alone or S. mutans complexed with a MAb directed against the major surface protein P1. Significant changes in the subclass distribution, as well as the specificity, of anti-P1 serum immunoglobulin G antibodies were demonstrated in groups of mice which received S. mutans coated with the anti-P1 MAb versus those which received S. mutans alone. Alterations in the humoral immune response were dependent on the amount of anti-P1 MAb used to coat the bacteria. In addition, differences in the anti-P1 immune responses were observed between groups of mice immunized via oral versus intranasal routes. In summary, an exogenous MAb complexed with a streptococcal antigen prior to mucosal immunization can influence the immunoglobulin isotype and specificity of the host humoral immune response against the antigen.

2000 ◽  
Vol 23 (6) ◽  
pp. 613-621 ◽  
Author(s):  
Hyo J. Hong ◽  
Jae W. Lee ◽  
Sung Sup Park ◽  
Young Jun Kang ◽  
Sun Young Chang ◽  
...  

2020 ◽  
Vol 21 (4) ◽  
pp. 1277 ◽  
Author(s):  
Ana Raquel Maia ◽  
Rodrigo Reyes-Ramírez ◽  
Marjorie Pizarro-Guajardo ◽  
Anella Saggese ◽  
Pablo Castro-Córdova ◽  
...  

Clostridioides difficile, formerly known as Clostridium difficile, is a spore-forming bacterium considered as the most common cause of nosocomial infections in developed countries. The spore of C. difficile is involved in the transmission of the pathogen and in its first interaction with the host; therefore, a therapeutic approach able to control C. difficile spores would improve the clearance of the infection. The C-terminal (CTD) end of BclA2, a spore surface protein of C. difficile responsible of the interaction with the host intestinal cells, was selected as a putative mucosal antigen. The BclA2 fragment, BclA2CTD, was purified and used to nasally immunize mice both as a free protein and after adsorption to the spore of Bacillus subtilis, a well-established mucosal delivery vehicle. While the adsorption to spores increased the in vitro stability of BclA2CTD, in vivo both free and spore-adsorbed BclA2CTD were able to induce a similar, specific humoral immune response in a murine model. Although in the experimental conditions utilized the immune response was not protective, the induction of specific IgG indicates that free or spore-bound BclA2CTD could act as a putative mucosal antigen targeting C. difficile spores.


2010 ◽  
Vol 89 (3) ◽  
pp. 495-500 ◽  
Author(s):  
G. Gómez-Verduzco ◽  
G. Téllez ◽  
A.L. Quintana ◽  
A. Isibasi ◽  
V. Ortiz-Navarrete

Sign in / Sign up

Export Citation Format

Share Document